Name: Latest research reports of Cohance Lifesciences Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Cohance Lifesciences Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Cohance Lifesciences Ltd.

NSE: COHANCE | BSE: 543064 | ISIN: INE03QK01018 | Industry: Pharmaceuticals
| Expensive Performer

1031.2500 13.30 (1.31%)

NSE Jul 14, 2025 15:31 PM

26.53% Gain from 52W Low

Volume: 201.4K

Cohance Lifesciences Ltd.

29 May 2025

1031.25

1.31%

Cohance Lifesciences (BUY): To remain on a high growth trajectory

Buy: Cohance Lifesciences Ltd.

Target

BOB Capital Markets Ltd.

4QFY25 consolidated proforma sales were 11.4% above our estimates; EBITDA/APAT was -0.4% and -5.9% below estimates

Cohance Lifesciences Ltd. is trading below its 50 day SMA of 1031.4